TSHA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy now. TSHA is trading near first support (4.457) at ~4.51 after a mild decline, while options positioning is strongly call-skewed and Wall Street targets/rating actions have turned decisively bullish on the Rett syndrome program. With hedge funds aggressively increasing buying and multiple recent price-target hikes, the risk/reward from this support area is attractive for an impatient buyer looking for near-term upside, despite weak/early technical momentum and insider selling.
Price/Trend: Post-market ~4.51 (-1.31% regular session), sitting just above S1 support at 4.457 and below the pivot 4.734 (a near-term reclaim level). Momentum: MACD histogram -0.0455 (below zero) but negatively contracting, implying bearish momentum is weakening (potential stabilization rather than a confirmed reversal). RSI: RSI(6) ~36.8, leaning toward the lower end of neutral—consistent with short-term weakness but also close to “oversold-ish” conditions that can produce bounces. Moving Averages: Converging MAs suggest consolidation; a push back above the pivot (4.734) would improve the short-term trend. Levels to watch: Support 4.457 then 4.286; Resistance 5.011 then 5.182.
Intellectia Proprietary Trading Signals
Bottom line (technical): Not a clean breakout setup yet, but the stock is sitting at a logical buy zone near support where downside is more defined and a rebound is plausible if it reclaims 4.734 and then 5.01.
Analyst-driven momentum: Multiple recent target raises and upgrades centered on Rett syndrome program progress and FDA-aligned study design (REVEAL).
Hedge fund flow: Reported hedge fund buying up sharply (+649.63% last quarter), supporting institutional appetite.
Options positioning: Strong call skew (OI and volume) implies bullish speculative sentiment.
Technical location: Price sitting near S1 support (4.457), improving tactical entry positioning versus chasing higher levels.
Business stage/financial visibility: Revenue dropped to 0 (pre-commercial biotech profile), keeping the stock highly catalyst-dependent.
Latest reported quarter: 2025/Q3. Revenue: Dropped to 0 (-100% YoY), consistent with a development-stage biotech. Net income: Improved to -$32.733M (loss narrowed ~28.24% YoY), indicating reduced burn versus prior year. EPS: -0.09 (worse by ~10% YoY per provided data). Overall: Financials are dominated by R&D spend and cash burn dynamics rather than operating revenue—price action will be driven primarily by clinical/regulatory progress rather than near-term fundamentals.
Recent trend: Clear positive shift with upgrades/target raises clustered from early Nov 2025 through early Jan 2026.
